The period in brief – financial summary for the third quarter
- Net sales amounted to
SEK 0 million (SEK 0 ). - R&D expenses amounted to
SEK 9,2 million (SEK 8,7 million ). - Operating income for the third quarter amounted to
SEK -10,5 million (SEK -10,7 million ). - Income after financial items for the third quarter amounted to
SEK -10,7 million (SEK -10,9 million ). - Earnings per share, before and after dilution, for the third quarter amounted to
SEK -0.13 (SEK -0.19 ). - Cash flow from operating activities for the third quarter amounted to
SEK -8,8 million (SEK -14,1 million ). - As of
September 30 , equity amounted toSEK 66,1 million (SEK 84,1 million ) orSEK 0.81 (SEK 1.50 ) per share. - The equity/assets ratio on
September 30 , was 84 percent (89 percent). - Cash and cash equivalents on
September 30 , amounted toSEK 58,2 million (SEK 68,2 million ).
Significant events during the second quarter
Peter Selin started as new CEO ofKancera AB onJuly 1, 2023 .Kancera announced that Dr.Markus Jerling has been appointed as new CMO, effective as ofSeptember 1, 2023 .Kancera reported that all lab analyses of data related to the primary and secondary endpoints have been completed, the study database has been validated and locked and the study sponsor, NHS, is conducting statistical analysis. Further,Kancera reported that top line results are expected to be presented in Q4 2024.Kancera reported that the USPTO has granted a product patent for KAND567, manufactured according to Kancera’s patented manufacturing process, which enablesKancera to apply for data exclusivity and market protection for up to 7.5 years for the first indication approved inthe United States .Kancera reported that the regulatory review of Kancera’s application to conduct a phase I study of KAND145 is ongoing and that approval is expected in Q4 2023.
Important events after the end of the period
Kancera has reported that the application to conduct a phase I study of KAND145 has received regulatory approval.Kancera has reported that the top line results from the FRACTAL study will be delayed to the end of December this year, due to lack of resources within the NHS to finalize the statistical analysis.Kancera is reporting that the first subjects in the phase I study have been dosed with KAND145.Kancera is reporting that the preclinical projects KAN571 (ROR1 inhibitor) and KAN757 (PFKFB3 inhibitor) have been terminated on commercial grounds.
About
For further information:
Visit Kancera’s web page: https://www.kancera.com/en and see
Presentation of Interim Report for Q3 2023
or contact:
CEO,
peter.selin@kancera.com or +46 (0)8-5012 60 80
© Modular Finance, source